Marina Charitou, MD
Endocrinology, Diabetes & Metabolism · East Setauket, NYNPI 1518053248
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $178,251 of the $212,266 with a category attached, or 84.0%. Insulet Corporation accounts for 73.2% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $116,715, more than ten times the $11,184 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $547.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$155K
- Dexcom, Inc.$52K
- Abbott$3K
- Medtronic$1K
- BETA Bionics, Inc.$297
- Sanofi-aventis U.S. LLC$168
- plus $687 from 8 others
What the payments were for
- Consulting fees$8,8014%
- Speaking & faculty fees$178,25184%
- Travel & lodging$16,9108%
- Food & beverage$8,2784%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 299 | $155,308 |
| Dexcom, Inc. | 62 | $51,566 |
| Abbott | 4 | $2,921 |
| Medtronic | 6 | $1,319 |
| BETA Bionics, Inc. | 3 | $297 |
| Sanofi-aventis U.S. LLC | 3 | $168 |
| Tandem Diabetes Care, Inc. | 2 | $162 |
| Cequr Corporation | 2 | $156 |
| Novo Nordisk | 2 | $153 |
| Xeris Pharmaceuticals, Inc. | 1 | $128 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Antares Pharma, Inc. | 1 | $21 |
| Mannkind Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$151,066
- DEXCOM G7 GSS (161)$30,575
- DEXCOM G6 TRANSMITTER$10,656
- DEXCOM CGM$5,050
- DEXCOM G6 CGM SYSTEM$4,600
- FreeStyle Libre Pro$2,886
- DEXCOM STELO GLUCOSE BIOSENSOR$2,412
- Minimed 670G System$1,250
- iLet Bionic Pancreas$633
- iLet Insulin Infusion Kit Inset$211
- iLet Insulin Infusion Kit Contact Detach$211
- CeQur Simplicity$136
- GVOKE HYPOPEN$128
- RYBELSUS$125
- TZIELD$125
How this compares
$212,266 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 212 | $308,203 |
| MounjaroTirzepatide | 259 | $307,124 |
| TrulicityDulaglutide | 129 | $192,272 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 93 | $131,082 |
| JardianceEmpagliflozin | 71 | $92,662 |
| RybelsusSemaglutide | 29 | $42,630 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $41,300 |
| FarxigaDapagliflozin Propanediol | 22 | $27,983 |
| JanuviaSitagliptin Phosphate | 20 | $24,747 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $23,960 |
| NovologInsulin Aspart | 53 | $21,257 |
| Novolog FlexpenInsulin Aspart | 60 | $19,718 |
| HumalogInsulin Lispro | 41 | $15,561 |
| Gvoke Hypopen 2-PackGlucagon | 22 | $13,954 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $12,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $153 | $372,090294 claims |
| Sanofi-aventis U.S. LLCLantus | $168 | $97611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in East Setauket
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.